HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,900.00
-25.00 (-0.64%)
At close: Mar 20, 2026
Market Cap475.20B -63.5%
Revenue (ttm)114.33B +147.1%
Net Income-178.33B
EPS-1,434.56
Shares Out121.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume304,268
Average Volume404,576
Open3,925.00
Previous Close3,925.00
Day's Range3,900.00 - 3,995.00
52-Week Range3,105.00 - 9,510.00
Beta-0.04
RSI49.02
Earnings DateMar 26, 2026

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements